Cancer Immunotherapy Market Worth 119.39 Billion USD by 2021

India - English

News provided by

Sep 15, 2016, 09:30 ET

PUNE, India, September 15, 2016 /PRNewswire/ --

According to a new market research "Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021", published by MarketsandMarkets, the global Cancer Immunotherapy Market is expected to reach USD 119.39 Billion by 2021 from USD 61.9 Billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.

(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 43 market data Tables and 69 Figures spread through 145 Pages and in-depth TOC on "Cancer Immunotherapy Market"

http://www.marketsandmarkets.com/Market-Reports/cancer-immunotherapy-market-197577894.html

Early buyers will receive 10% customization on this report.

In this report, the global Cancer Immunotherapy Market has been segmented based on type, application, end user, and region. On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021. The high growth in this segment is primarily attributed to the high success rate of these inhibitors.

On the basis of applications, the global Cancer Immunotherapy Market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others. The lung cancer segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the increasing prevalence of this type of cancer and rising demand for advanced treatment options.

On the basis of end users, the global Cancer Immunotherapy Market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global Cancer Immunotherapy Market in 2016. The rise in healthcare spending has resulted in the increasing use of immunotherapeutic drugs in hospitals.

Based on regions, the global Cancer Immunotherapy Market is segmented into North America, APAC, Europe, and the Rest of the World (RoW). North America is expected to account for the largest share of the market in 2016. Growth in this regional segment is driven by factors such as increase in patient pool and initiative taken by the government for the development of cancer immunotherapy.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=197577894

Key players in the Cancer Immunotherapy Market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffmann-La Roche AG (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

Browse Related Reports:

Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020.

http://www.marketsandmarkets.com/Market-Reports/immunotherapy-drug-market-137717755.html

Regenerative Medicines Market by Therapy (Cell Therapy, Gene Therapy, Immunotherapy, Tissue Engineering), Product (Cell-Based, Acellular), Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Cardiovascular, Central Nervous System), Region - Global Forecast to 2021.

http://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html

About MarketsandMarkets:

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
MarketsandMarkets
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Telephone No: 1-888-600-6441.
Email: [email protected]

Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets